Sanofi-Synthelabo to buy out Indian JV
French drugmaker Sanofi-Synthelabo is to buy out the 50% stake held byTorrent Pharmaceuticals in the companies' joint-venture Sanofi-Torrent India. The reason for the buy-out is understood to be the decision taken by Torrent to market Sanofi-Synthelabo's antiplatelet drug Plavix/Iscover (clopidogrel) in India at a much lower price than the French firm wants.
Once the buy-out is completed, Torrent brands including its anti-Parkinson's agent Tidomet (levodopa/carbidopa) will be returned and Sanofi-Synthelabo will market its own drug products in India. However, Torrent will continue to make drugs for the French firm, which has no manufacturing base in India.
Torrent profits take a fall
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze